Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144375 | 1.00 | TSHR (0.61) | TSHRRAB9AHDAC1CES2CES1 | |
| SCHEMBL21365979 | 0.83 | ALDH1A1 (0.45) | TSHRRAB9ACES2CES1KMT2A | |
| SCHEMBL6630778 | 0.83 | ALDH1A1 (0.45) | TSHRRAB9ACES2CES1KMT2A | |
| SCHEMBL7902858 | 0.83 | ALDH1A1 (0.45) | TSHRRAB9ACES2CES1KMT2A | |
| SCHEMBL9709665 | 0.81 | TSHR (0.68) | TSHRRAB9AHDAC1CES2CES1 | |
| SCHEMBL9709670 | 0.81 | TSHR (0.68) | TSHRRAB9AHDAC1CES2CES1 | |
| SCHEMBL497126 | 0.72 | — | — | |
| SCHEMBL28738208 | 0.72 | KMT2A (0.67) | TSHRRAB9AHDAC1CES2CES1 | |
| SCHEMBL12849961 | 0.72 | — | — | |
| SCHEMBL10344990 | 0.72 | HDAC1 (0.62) | TSHRRAB9AHDAC1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | claimed |
| EP-1386901-B1 | Method for producing an optically active beta-amino acid | TAKASAGO PERFUMERY CO LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-7893296-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | MATSUMURA KAZUHIKO | 2006-06-08 | — | — | US | disclosed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | AADAT, DAO, BCAT2 | TSHR 2633/4885RAB9A 1112/4885HDAC1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.